The preliminary results for Johnson & Johnson’s (J&J) late-stage Covid-19 vaccine trial should be available by January 21 and will then be submitted to the US Food and Drug Administration, according to the protocol chair for the local arm of the trial, Medical Research Council president Glenda Gray.

SA has a particularly keen interest in J&J’s shot because local pharmaceutical manufacturer Aspen Pharmacare secured a deal with the US-based firm in November that will see it fill and package as many as 300-million vials per year at its sterile plant in Port Elizabeth...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.